Originally published In Press as doi:10.1074/jbc.M200737200 on March 8, 2002
J. Biol. Chem., Vol. 277, Issue 21, 19037-19041, May 24, 2002
Nuclear Injection of Anti-pigpen Antibodies Inhibits Endothelial
Cell Division*
Mark C.
Alliegro
and
Mary Anne
Alliegro
From the Department of Cell Biology and Anatomy, Louisiana State
University Health Sciences Center, New Orleans, Louisiana 70112
Received for publication, January 23, 2002, and in revised form, March 1, 2002
 |
ABSTRACT |
Endothelial cell proliferation is required for
angiogenesis in both embryonic and adult tissues. In rat brain
tumors, it has recently been shown that the nuclear protein pigpen is
expressed selectively in endothelial cells of developing
microvasculature but not in the established peritumoral vessels (Blank,
M., Weinschenk, T., Priemer, M., and Schluesener, H. (2001)
J. Biol. Chem. 276, 16464-16468). This finding
suggests that pigpen may be important for promoting the
undifferentiated, or "angiogenic" endothelial cell phenotype. Our
studies show that pigpen protein and mRNA are expressed in actively
dividing endothelial cells and down-regulated as they become confluent.
Protein distribution is regulated in a cell cycle-dependent
manner. We conclude that this expression pattern is important for and
not simply ancillary to proliferation because nuclear microinjection of
anti-pigpen Fab fragments inhibited endothelial cell division.
Moreover, expression of the proliferating cell marker Ki67 was
inhibited in antibody-injected cells. The absence of Ki67 suggests exit
from rather than arrest within (for example, at the G1/S
interface) the cell cycle. Together with earlier observations on the
structure and expression of this molecule, our data support the
hypothesis that pigpen helps regulate endothelial cell differentiation state.
 |
INTRODUCTION |
Angiogenesis is the development of new blood vessels from existing
vasculature. It begins early and continues throughout embryonic development, extending early rudiments of the vascular system to meet
the nutritive requirements of growing tissues. In adult tissues
angiogenesis is a relatively rare and tightly regulated event.
Endothelial cells (EC)1 must
therefore be transformed from a quiescent, non-proliferative state to
an undifferentiated/proliferative phenotype that provides the building
blocks and framework for new vessels. This process occurs normally
during wound healing and cyclic reproductive events but can also be
triggered by a variety of pathological conditions resulting in
considerable tissue damage (1). New blood vessel development is
critical for tumor growth and metastasis, for example. In the eye,
angiogenesis is involved in more than 20 disorders (2), including
neovascular glaucoma, age-related macular degeneration, and
proliferative diabetic retinopathy.
Great progress has been made in our understanding of extracellular
factors governing angiogenesis. Control of EC phenotype is generally
thought to be regulated by a balance of stimulators and inhibitors. We
have a great deal more to learn about the downstream effectors of
angiogenesis, however, especially the nuclear factors that convert
incoming signals into the new genetic program. Induction of several
well known nuclear regulatory molecules has been shown to accompany
angiogenic stimulation. For example, analogues of the immediate early
genes, c-fos, c-jun, and egr-1
are induced in phorbol 12-myristate 13-acetate-stimulated EC (3).
Phorbol 12-myristate 13-acetate also induces EDG-2, a
human homologue of the Xenopus G10 protein. Induction of the
DNA-binding homeobox protein Hox D3 has been shown not only to
accompany but to trigger expression of the angiogenic phenotype in
avian EC (4). Still there are many gaps to be filled. It is certain
that other characterized regulatory proteins will be fitted into this
scheme, and equally likely that new ones will be discovered.
There is evidence to suggest that the nuclear protein pigpen functions
in the proliferative phase of angiogenesis. This molecule displays a
transcription activation domain as well as consensus motifs associated
with RNA binding (5). In the latter case, we have evidence to suggest
that pigpen interacts selectively with mRNAs, notably those of
positive cell cycle regulators such as Bub1, E2F4, and katanin (6).
Importantly, it was recently shown that pigpen is highly expressed in
rat brain tumor microvessels but is absent in mature brain vasculature,
even in zones immediately adjacent to the tumor (7). Together with
other observations on the up-regulation of pigpen in wounded vascular
cell monolayers (5, 7, 8), these data suggest that pigpen's expression pattern underlies a functional role in regulating EC phenotype.
We tested the hypothesis that pigpen is important for cell division by
microinjection of anti-pigpen Fab fragments into the nuclei of EC in
proliferating cultures. More than 200 individual cells were injected,
tracked, and assayed for progression through mitosis. We found that
cell division was inhibited by ~50%. Anti-pigpen arrested cells
appeared to be thrown out of the cell cycle as judged by the absence of
the ubiquitous cycling cell marker Ki67. Our results suggest that
pigpen expression is not only coincident with proliferation in EC but
is important for maintaining the proliferative/undifferentiated
phenotype required for the early stages of angiogenesis.
 |
EXPERIMENTAL PROCEDURES |
Source and Culture of Cells--
Fetal bovine aortic EC used in
this study were isolated according to the methods of Fenselau and Mello
(9) and have been characterized and described previously (10). Cells
were cultured on sterile glass coverslips in minimal essential medium
containing 15% fetal bovine serum plus 100 units/ml penicillin and 100 µg/ml streptomycin. In some experiments, cells were arrested in
G1 with a combination of amiloride + bumetanide (AB) as
described by Panet et al. (11). Briefly, confluent cells
were harvested by trypsinization, replated at 1:5 dilution on sterile
glass coverslips, and cultured in standard 6-well tissue culture plates
overnight. A fresh (100× stock) solution of 100 mM
amiloride and 10 mM bumetanide in Me2SO (Sigma) was prepared prior to each experiment. Tissue culture medium in the wells was replaced with 2 ml of fresh media, and 20 µl of AB stock was added to bring the final concentrations to 1 mM amiloride, 100 µM bumetanide, and 1%
Me2SO. Control samples were treated with 1%
Me2SO alone. Cells were then cultured in AB long enough to
traverse one cycle and ensure uniform arrest in G1 (20 h)
and prepared for indirect immunofluorescence.
Immunological--
The specificity of polyclonal anti-pigpen was
examined by Western blot analysis using methods described previously
(5). Whole EC lysates were resolved by polyacrylamide gel
electrophoresis, transferred to nitrocellulose, and probed with
anti-pigpen or preimmune serum from the same rabbit. The detection
system used was a peroxidase-conjugated secondary antibody with
hydrogen peroxide and 1,4-dichloronaphthol substrates. India ink was
used to stain total protein in parallel lanes. The results of Western
analysis are shown in Fig. 1. No protein
bands were detected with preimmune serum at dilutions ranging from
1/500 to 1/5000. A single band migrating at 67 kDa (predicted migration
for pigpen) was detected in anti-pigpen probed lanes over the same
dilution range.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 1.
Selectivity of anti-pigpen in Western
blots. Lane A, total protein, stained with india ink;
lane B, probed with anti-pigpen at 1/1000 dilution;
lane C, preimmune control at 1/1000 dilution. Each lane was
loaded with 50 µg of whole EC lysate. Positions of kDa standards
indicated on the left. The diffuse band and dots at the
bottom of lane C are dye (pyronin Y) and hand
notation, respectively, used to identify the blot lane.
|
|
For immunohistochemistry of cultured cells, culture medium was
removed with three brief rinses in PBS prior to fixation in 2.5%
paraformaldehyde in PBS (5 min) followed immediately by
permeabilization and post-fixation in 0.5% Triton X-100 (3 min) and
100% methanol (8 min,
20 °C). Three 10-min rinses in PBS were
followed by a 30-min incubation in blocking solution (1.5% goat serum
in PBS) and 60 min in primary antibody. Anti-pigpen was diluted at
1/500 in blocking solution. Monoclonal anti-Ki67, purchased from
Immunotech (Marseille, France), is supplied in its own
blocking solution and was used directly from the bottle. Fluorescently
labeled secondary antibodies were purchased from Sigma. Coverslips were
mounted on glass slides with Vectashield (Vector Laboratories,
Burlingame, CA).
IgGs for microinjection were purified by protein A-Sepharose affinity
chromatography and reduced to Fab fragments by papain digestion as
described by Goding (12). Fab fragments were collected in the effluent
of a subsequent protein A affinity column and pressure-dialyzed into
microinjection buffer using Centricon microfiltration devices (Amicon).
The IgG concentration in microinjection buffer was 1 mg/ml.
Microinjection--
Cells cultured on CELLocate (Eppendorf)
glass coverslips were microinjected using an Eppendorf automated
microinjection system with duration and pressure settings of 0.5 s
and 30 hectopascals, respectively. The microinjection buffer has
been described by O'Keefe et al. (13) and contains 15 mg/ml
lysine-fixable 70-kDa Texas Red-conjugated dextrans, 10 mM
NaH2PO4, and 70 mM KCl, pH 7.2. Following microinjection cells are washed two times in minimum essential medium + 15% fetal calf serum and cultured under
standard conditions until fixed for subsequent analysis. Pre-immune Fab fragments were injected under identical conditions as a control in all experiments.
 |
RESULTS |
Pigpen Expression Is Regulated--
Pigpen is expressed
ubiquitously in proliferating EC cultures; however, both the protein
and its mRNA are sharply down-regulated when cells become confluent
(Fig. 2). These observations are
consistent with other reports linking pigpen expression to the
undifferentiated phenotype both in vitro and in
vivo (5, 7, 8).2

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 2.
Pigpen expression in proliferating and
quiescent EC. Shown are sparse (A), subconfluent
(B), and confluent (C) EC cultures labeled
with anti-pigpen. D shows Northern analysis of pigpen
mRNA levels in three equivalent cultures, from left to
right. Each lane is loaded with 2 µg of EC
poly(A)+ RNA. Protein and mRNA expression are
dramatically reduced as cells attain a quiescent phenotype. Expression
is up-regulated rapidly and locally if a wound is made in the cell
monolayers (5,8).
|
|
Pigpen is expressed at all stages of the cell cycle, but its
distribution is regulated in a cell cycle-dependent manner
(Figs. 3 and
4). In G1 there are ~17
pigpen-containing foci (coiled bodies; CB) per cell. This number
declines to 10 during progression through S and G2 phases.
During this same period nuclear envelope staining appears more
prominent. Pigpen foci reach a minimum average of 1 per cell during
anaphase and then begin to increase in number again before the
completion of M phase. Two observations consistent with past findings
were that: 1) pigpen-containing CB can be found outside the nuclear
zone during late telophase (and indeed may persist in the cytoplasm, as
may be noted in Fig. 2B); 2) throughout M phase
pigpen-containing CB seem to associate preferentially with the
mediolateral, poleward aspect of chromosomes. It is possible that this
localization is passive in some respect, e.g. if CB are
excluded from the metaphase figure and remain pressed against the
periphery of poleward-moving chromosomes. However, their initial juxtachromosomal positioning in metaphase, when net chromosomal movement is zero or is directed toward the metaphase plate, would appear to discount this possibility and suggest some bona
fide interaction.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 3.
Pigpen is expressed throughout the
endothelial cell cycle; its distribution is cyclically regulated.
Cells were double-labeled with anti-pigpen (shown in
green) and anti-Ki67 (red), the latter was used
to determine cell cycle phase. Overlays of the two images are shown in
the right-hand column. A-C, G1
phase; D-F, S/G2; G-I, metaphase;
J-L, anaphase; M-O, telophase. A marked change
in the number of pigpen-containing foci (coiled bodies) was observed,
with a maximum in G1 and a minimum in anaphase
(quantitation shown in Fig. 3).
|
|

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 4.
Cyclic fluctuation in the population of
pigpen-containing coiled bodies. Data were derived by random
selection of at least 100 Ki67-staged cells in three separate trials
(range from 100 to 103 cells). Vertical bars represent
standard errors. Data for M phase are divided into prophase
(P), metaphase (M), anaphase (A), and
telophase (T). All variations from stage to successive stage
were determined to be statistically significant (p < 0.05) by analysis of variance.
|
|
Pigpen Is Important for Endothelial Cell Proliferation--
Given
the multifunctional nature of pigpen (including transcription
activation and RNA binding domains), its down-regulation in quiescent
EC, and its ubiquitous expression in cycling cells, it is a reasonable
hypothesis that it functions in maintenance of the proliferating
(dedifferentiated) EC phenotype. To test this hypothesis, we examined
the effects of nuclear-injected anti-pigpen antibodies on EC
proliferation. The microinjection buffer included 70-kDa Texas
red-labeled dextrans that both enabled tracking of individual cells on
the day following injection and provided a simple means to assay for
progression through M phase via fluorescence redistribution. In two
experiments, slightly over 200 cells were injected with anti-pigpen Fab
fragments or pre-immune Fab fragments as a control. The injected cells
were cultured for 20 h to permit at least one round of cell
division, then fixed. Divided cells were identified by cytoplasmic
fluorescence due to redistribution of dextrans upon nuclear envelope
breakdown (Fig. 5). In cells that had not
entered M phase, dextrans remained compartmentalized in the nucleus. We
found that the difference between control and experimental groups was
marked (Fig. 6A); control
cultures exhibited almost twice the number of divided cells compared
with those injected with anti-pigpen Fab fragments.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 5.
Fluorescence redistribution in dividing
endothelial cells. Anti-pigpen Fab fragments were injected into
the nucleus of 200 EC. The microinjection buffer included labeled
dextrans as a marker, and a fluorescence redistribution assay was used
to determine the fate of each cell 20 h later. In undivided cells,
Texas Red-labeled dextrans remain compartmentalized in the nucleus
(A). Nuclear envelope breakdown at the onset of M phase
redistributes dextrans throughout the cell
(B).
|
|

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 6.
Microinjection of anti-pigpen inhibits
endothelial cell proliferation. Anti-pigpen Fab fragments
inhibited EC division by ~50% (A). This figure includes
only cells showing no redistribution of Texas Red-labeled dextrans
(i.e. arrested prior to prophase). In addition, a marked
increase in the number of binucleate cells (24%) was observed in
anti-pigpen versus pre-immune injected cells (B).
The incidence of binucleate cells in the latter group was identical to
that observed in uninjected cultured EC (5%). Total inhibition,
combining cells that failed to undergo karyokinesis with those
progressing through karyokinesis but failing to undergo cytokinesis, is
~72%.
|
|
It may be that our estimate for inhibition is conservative, depending
on whether or not pigpen functions during a discrete phase of the cell
cycle. If pigpen were required during G1, for example, then
cells injected during S or G2 would likely progress through
mitosis and be tallied among the uninhibited. This may be reflected in
the relatively high incidence of binucleate cells observed in the
experimental group (24 versus 5% for controls; Fig.
6B). One explanation for this finding is that some cells were injected too late in the cell cycle to block karyokinesis but soon
enough to prevent progression through cytokinesis. It is also possible
that pigpen affects both karyokinesis and cytokinesis through
relatively independent mechanisms and that the latter was more
sensitive to antibody injection. Regardless of the precise mechanism,
if these cells that failed to undergo cytokinesis are added to those
blocked prior to karyokinesis, the level of inhibition resulting from
injection of anti-pigpen approximates 72%.
Effect of Anti-pigpen Injection on Ki67 Expression--
Ki67 is a
nuclear protein expressed in proliferating cells but not in non-cycling
(G0) cells. Similar to the proliferating cell nuclear
antigen and several other well characterized molecules, Ki67 exhibits a
repeating pattern of regulated expression and redistribution during the
cell cycle (14). It has been used extensively as a marker in human
tumor diagnostics (the Ki67 labeling index) and as a reliable cell
cycle monitor (see Fig. 3, for example). During G1, Ki67 is
present in the nucleoplasm at low levels in a fine, granular pattern.
In S and G2 phases Ki67 becomes highly concentrated in
nucleoli, and in M phase anti-Ki67 stains chromosomes intensely. EC
arrested in G1 with AB exhibit a Ki67 expression pattern
consistent with the G1 conformation seen in cycling cells. An example is shown in Fig. 7A
to be compared with arrest induced by anti-pigpen injection. In the
latter cells, Ki67 expression was observed to be greatly attenuated and
often completely ablated (Fig. 7, B-D). The lack of Ki67 in
these cells suggests that they are not arrested within the cell cycle,
as are AB-arrested cells, but have exited the cell cycle and entered a
more differentiated state.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 7.
Anti-pigpen-induced down-regulation of Ki67
expression. Cells were fixed and prepared for immunofluorescence
20 h after treatment to block proliferation. In A, EC
were arrested in G1 with amiloride-bumetanide for
comparison and labeled with a monoclonal antibody to the cell cycle
marker Ki67. The antigen is expressed in the fine, granular pattern
characteristic of cells in G1 (see Fig. 2A, for
example). In anti-pigpen arrested EC (B-D), however, Ki67
antigen was not detected. B, nucleus of an injected cell
viewed with phase contrast. The grid markings of the CELLocate
coverslip visible in this panel are outlined in white in
C and D. C is the same cell, showing
fluorescence of Texas Red-conjugated dextrans. D, same cell
labeled with anti-Ki67.
|
|
We examined the distribution of two other nuclear antigens in injected
cells including the nucleolar protein fibrillarin and the spliceosomal
protein SC35. In both cases the distribution and apparent expression
level appeared indistinguishable from control (pre-immune) or
non-injected cells (Fig. 8). These
results suggest that the effects of anti-pigpen injection on Ki67
expression and EC proliferation were not likely due to nonspecific or
widespread effects on nuclear organization.

View larger version (7K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of anti-pigpen injection on
spliceosome and nucleolar organization. The results suggest that
the effects of anti-pigpen injection on Ki67 expression and EC
proliferation were not likely due to nonspecific or widespread effects
on nuclear organization. A and C show injected
cells visualized with Texas Red-conjugated dextrans. An additional,
uninjected cell is present in each panel, positions marked by
arrows. Injected and uninjected cells can be seen in
B and D, visualized by immunofluorescence with
anti-fibrillarin and anti-SC35, respectively.
|
|
 |
DISCUSSION |
Pigpen's highly regulated expression pattern both in
vitro (5, 8) and in situ (8),2 coupled with
bioactivities and structural elements including a zinc finger,
transcription activation, and RNA and carbohydrate binding domains (6),
provides compelling circumstantial evidence that it is a regulator of
EC phenotype. Additional evidence that this molecule is involved in
angiogenesis was recently reported by Blank et al. (7) using
an experimental rat brain glioma model. Pigpen was highly expressed in
newly forming microvessels within the tumor mass but was notably absent
from mature vessels, even in peritumoral zones.
In this report we provide the first experimental evidence to support
the hypothesis that pigpen plays a role in angiogenesis via regulation
of EC proliferation. We found that pigpen expression is not only
restricted to proliferating EC, but cell cycle progression can be
substantially perturbed by microinjection of anti-pigpen antibodies in
the nucleus of proliferating EC. Without EC proliferation, developing
tissues, whether embryonic or pathologic, lack the primary building
blocks and scaffolding required for new blood vessel development.
Given the variety of structural motifs the protein exhibits and its
subcellular distribution, pigpen could exert its influence at multiple
levels from gene activation to RNA processing or transport. Moreover,
its expression throughout the cell cycle, marked by a regulated
distribution pattern, make it possible for pigpen to play different
roles at different times. Identifying and following the biogenesis of
gene products downstream from pigpen will enable us to define its function(s).
 |
ACKNOWLEDGEMENTS |
Anti-SC35 was generously provided by Dr.
Joseph Gall and anti-human fibrillarin by Dr. David Spector.
 |
FOOTNOTES |
*
This work was supported by grants from the National
Institutes of Health and the Louisiana State University Health Sciences Center Stanley S. Scott Cancer Center.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Cell Biology
and Anatomy, Louisiana State University Health Sciences Center, 1901 Perdido St., New Orleans, LA 70112. Tel.: 504-568-7618; Fax:
504-568-4392; E-mail: mallie@lsuhsc.edu.
Published, JBC Papers in Press, March 8, 2002, DOI 10.1074/jbc.M200737200
2
S. R. Alappat, M. Zhang, M. A. Alliegro, M. C. Alliegro, and C. A. Burdsal, submitted for publication.
 |
ABBREVIATIONS |
The abbreviations used are:
EC, endothelial cell(s);
AB, amiloride + bumetanide;
CB, coiled bodies.
 |
REFERENCES |
| 1.
|
Folkman, J.
(1995)
Nat. Med.
1,
27-31[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Folkman, J.,
and Shing, Y.
(1992)
J. Biol. Chem.
267,
10931-10934[Free Full Text]
|
| 3.
|
Hla, T.,
Jackson, A. Q.,
Appleby, S. B.,
and Maciag, T.
(1995)
Biochim. Biophys. Acta
260,
227-229
|
| 4.
|
Boudreau, N.,
Andrews, C.,
Srebrow, A.,
Ravanpay, A.,
and Cheresh, D. A.
(1997)
J. Cell Biol.
139,
257-264[Abstract/Free Full Text]
|
| 5.
|
Alliegro, M. C.,
and Alliegro, M. A.
(1996)
Dev. Biol.
174,
288-297[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Alliegro, M. C.
(2001)
Cell Biol. Int.
25,
577-584[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Blank, M.,
Weinschenk, T.,
Priemer, M.,
and Schluesener, H.
(2001)
J. Biol. Chem.
276,
16464-16468[Abstract/Free Full Text]
|
| 8.
|
Kohler, A.,
Jostarndt-Fogen, K.,
Rottner, K.,
Alliegro, M. C.,
and Draeger, A.
(1999)
Anat. Embryol.
200,
313-323[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Fenselau, A.,
and Mello, R. J.
(1976)
Cancer Res.
36,
3269-3273[Medline]
[Order article via Infotrieve]
|
| 10.
|
Alliegro, M. C.,
Alliegro, M. A.,
Cragoe, E. J.,
and Glaser, B. M.
(1993)
J. Exp. Zool.
267,
245-252[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Panet, R.,
Snyder, D.,
and Atlan, H.
(1986)
Biochem. J.
239,
745-750[Medline]
[Order article via Infotrieve]
|
| 12.
|
Goding, J. W.
(1986)
Monoclonal Antibodies: Principles and Practice
, 2nd Ed
, Academic Press, New York
|
| 13.
|
O'Keefe, R. T.,
Mayeda, A.,
Sadowski, C. L.,
Krainer, A. R.,
and Spector, D. L.
(1994)
J. Cell Biol.
124,
249-260[Abstract/Free Full Text]
|
| 14.
|
Scholzen, T.,
and Gerdes, J.
(2000)
J. Cell. Physiol.
182,
311-322[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.